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Silencing RNAWe previously reported that overexpression of members of the Importin (Imp) superfamily of nuclear trans-
porters results in increased nuclear trafﬁcking through conventional transport pathways in tumour cells. Here
we show for the ﬁrst time that the extent of overexpression of Impβ1 correlates with disease state in the
MCF10 human breast tumour progression system. Excitingly, we ﬁnd that targeting Impβ1 activity through
siRNA is N30 timesmore efﬁcient in decreasing the viability of malignant ductal carcinoma cells compared to iso-
genic non-transformed counterparts, and is highly potent and tumour selective at subnanomolar concentrations.
Tumour cell selectivity of the siRNA effects was unique to Impβ1 and not other Imps, with ﬂow cytometric anal-
ysis showing N60% increased cell death compared to controls concomitant with reduced nuclear import efﬁcien-
cy as indicated by confocal microscopic analysis. This hypersensitivity of malignant cell types to Impβ1
knockdown raises the exciting possibility of anti-cancer therapies targeted at Impβ1.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Nuclear transport mediated by the Importin (Imp) superfamily of
transport receptors is central to eukaryotic cell function, with regulated
nuclear import and export of signalling molecules integral to processes
such as transcription, translation, cell cycle progression and apoptosis.
Imp expression is known to be altered in various types of cancers
(such as cervical, breast, ovarian and lung) [1], but that this may impact
on nuclear transport efﬁciency has only been demonstrated recently [2].
Importin β1 (Impβ1) is an important member of the Importin family of
nuclear transporters that is highly expressed in transformed cells such
as in Simian Virus 40 (SV40) large T-antigen-mediated transformation,
Human Papillomavirus-16 (HPV-16) E6/E7-transformed epithelial cells
and in gastric, bladder, breast and cervical cancer cell lines [2–5]. Highly
conserved in mammals, and ubiquitously expressed in human tissues
and cells, Impβ1 is critical for early embryonic development in the
mouse, worm and ﬂy [6,7] because of key roles in both interphase and
mitosis [8]. Through its ability to mediate interaction of transport com-
plexeswith the nucleoporin (Nup) proteins of the nuclear pore complex
(NPC), Impβ1 mediates nuclear import during interphase of a range of
different proteins, including of cargoes bound directly to Impβ1 suchian Virus 40;NT, non-targeting;
ry, Department of Biochemistry
00 Australia. Tel.: +613 9902as the signalling molecule parathyroid hormone-related protein PTHrP
[9], cyclin B1 [10], chromatin remodelling factors such as SOX9 [11]
and SRY [12] and basic loop helix factors such as activator protein-1
AP-1 and cAMP-response element-binding protein CREB [13]. Impβ1
can also mediate nuclear translocation of cargoes through the action
of Impα adapters that directly recognise other cargoes, such as the tu-
mour suppressor proteins pRb [14,15] and p53 [16], inducible transcrip-
tion factors such as the signal transducers and activators of transcription
(STATs) [17] and NF-κB family members [18]. Once in the nucleus, dis-
sociation of the transport complexes is effected by binding to Impβ1 of
the guanine binding protein Ran in activated GTP-bound form.
Impβ1 also plays a role after nuclear membrane breakdown during
entry into mitosis, where either it alone or together with Impα regu-
lates static spindle formation in a Ran-dependent manner by mediating
the delivery of spindle assembly factors (such as the nuclearmitotic ap-
paratus NuMA and microtubule associated TPX2 proteins) to spindle
poles [19], and has indirect effects on dynamic microtubule attachment
at kinetochores [20]. Impβ1 is critical to the formation of theNPC/nucle-
ar envelope architecture during telophase through its ability to recruit
Nups and other nuclear envelope components [21].
In this studywe use an isogenic breast tumour progressionmodel to
show for theﬁrst time that overexpression of Impβ1 is a key contributor
to increased Impα/β1-dependent nuclear transport activity, with a
strong correlation between the extent of transport activity and tumour
progression disease phenotype. Excitingly, we ﬁnd that tumour cell
types were highly sensitive to knockdown of Impβ1 but not various
other Imps, implying that increased Impβ1 levels/activity may play a
key role in tumour progression.
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2.1. Mammalian cell culture and siRNA treatment
The MCF10 breast tumour progression series was purchased from
Prof. Fred Miller/Dr. Steven Santner at the Karmanos Cancer Institute,
Detroit, MI, USA (under a materials transfer agreement which limits
the use of the cell lines to the purchaser only). It is composed of the
non-transformed MCF10A ductal breast epithelial cell line, its Ha-Ras
(G12V mutated) transformed benign counterpart MCF10AT, and two
fully malignant counterparts, the non-metastatic MCF10CA1h andmet-
astatic MCF10CA1a cell lines generated by serial trocar implantation
(passaging) in mice [22]. The 1BR3/1BR3.N human skin ﬁbroblast cell
pair [23] was obtained fromCarolineGarrett (Centre for Genome Stabil-
ity and Damage, Sussex, UK); the transformed derivative was generated
by transfection with a plasmid containing SV40 genomic sequences
for the early region composed of the transforming small and large
T-antigen products.
MCF10A (passage b 75), MCF10AT (passage b 71), MCF10CA1h
(passage b 60) and MCF10CA1a (passage b 105) cells were cultured
in DMEM/F12 Ham's media supplemented with 5% horse serum
(Invitrogen, Carlsbad, CA, USA), 1 mM sodium pyruvate, 10 mM
HEPES, 2 mM L-glutamine, 0.5 μg/ml hydrocortisone, 10 μg/ml bo-
vine insulin, 20 ng/ml human recombinant EGF and 100 ng/ml chol-
era toxin (all from Sigma-Aldrich, St. Louis, MO, USA), as previously,
whilst 1BR3 and 1BR3.N cells (both at passages b 18) were cultured
in DMEM supplemented with 15% FCS and 2 mM L-glutamine
(Invitrogen), as previously [2].
For Impβ1 titration, comparative Imp silencing efﬁciency and cell
killing assays in the MCF10 cell system, 2.3 × 105 cells were seeded
into 6 cm dishes, treated 24 h later with ONTARGETplus SMARTPool
siRNAs (pools of 4 different siRNAs from Dharmacon, GE Healthcare,
Little Chalfont, UK) speciﬁc for Impα1, Impα3, Exp-1, CAS, Impβ1 or
non-targeting control siRNA, where appropriate (see Supplementary
Table S1 for siRNA sequences), at the indicated doses using RiboCellIn
siRNA transfection reagent (BioCellChallenge, Toulon-Cedex, France)
according to manufacturer's instructions, and incubated for 48 h (day
2) before re-seeding onto 96- (3.3 × 103 cells) or 6- (1.0 × 105 cells)
well culture plates for XTT or confocal microscopic imaging and protein
analysis respectively. Twenty-four hours later (day 3), cells were
retreated with another dose of siRNA, and incubated for the indicated
time points prior to Western, microscopic and/or XTT analysis.2.2. Quantitative real-time reverse transcription-PCR
For analysis ofmRNAexpression levels, 0.7 × 106 cells were plated in
10 cm dishes and 48 h later RNA was isolated from cells using the
RNeasy mini kit (Qiagen, Venlo, Limburg, Netherlands) according to
the manufacturer's instructions, prior to DNAse digestion using
RNAase-free DNAse (Ambion) and reverse-transcription by ﬁrst strand
cDNA synthesis using 500 ng of total RNA and Superscript III Reverse
Transcriptase/random hexamers (Invitrogen). cDNA (20 ng) was then
ampliﬁed using the SensiMix SYBR Master Mix (Bioline, Alexandria,
NSW, Australia) and 1 μM Impβ1 forward and reverse primer mix
(sense: 5′-AAGCCGCAGATTCTGTCAGT-3′; anti-sense: 5′-TTCCAAGCAG
CTTTCCCTTA-3′). Quantitative RT-PCRwas performed using the Applied
Biosystems 7900HT Fast Real-Time PCR system (Applied Biosystems,
Life Technologies, Mulgrave, Victoria, Australia) for triplicate reactions.
The comparative threshold cycle (CT) method was used for the calcula-
tion of expression fold-change between normal and transformed cells,
and normalised to GAPDH (sense: 5′-TGCACCACCAACTGCTTAGC-3′;
anti-sense: 5′-GGCATGGACTGTGGTCATGAG-3′) and 18S (sense: 5′-
TCCCCCAACTTCTTAGAGG-3′; anti-sense: 5′-CTTATGACCCGCACTTAC
TG-3′) internal reference targets as determined from a set of tested
genes by the geNorm function on qBase (not shown) [24].2.3. Preparation of cell extracts and Western blotting
Cells were washed twice with ice-cold PBS prior to incubation in
ice-cold RIPA lysis buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA)
with fresh 5× EDTA-free complete protease inhibitor cocktail (Roche,
Indianapolis, IN, USA), scraped and lysed at 4 °C for 30 min and centri-
fuged at 10,000 g for 30 min at 4 °C to pellet insoluble material. The
total protein concentration in each extract was estimated using the
Bradford Dye Reagent (Bio-RAD, Hercules, CA, USA). Twenty micro-
grams of protein from each cell extract was then separated by SDS-
PAGE (10% reducing gel), transferred onto nitrocellulose membrane
(PALL Corporation, Port Washington, NY, USA) and probed with anti-
Impα1, Impβ1, Exp-1, CAS monoclonal (all from BD Biosciences, San
Jose, CA, USA) or anti-Impα3 polyclonal (Abcam, Cambridge, MA,
USA) primary antibodies, followedby the appropriate host IgG-HRP sec-
ondary antibody (Chemicon, Temecula, CA, USA) according to the
manufacturer's recommendations, and protein visualised using the
Western Chemiluminescence Reagent (from Perkin-Elmer, Wellesley,
MA, USA or Millipore, Bedford, MA, USA). The membranes were then
stripped of antibody using Western strip buffer (25 mM glycine, 1%
SDS, pH 2), blocked and re-probedwith anti-α/β tubulin (Cell Signaling,
Danvers, MA, USA) or -β actin (Abcam) antibodies followed by the ap-
propriate host-IgG-HRP secondary antibodies and visualised as previ-
ously. The intensity of the resulting bands for all proteins was
estimated by densitometry using an Alpha Imager (Alpha Innotec,
Santa Clara, CA, USA) for image capture and the 1D electrophoresis gel
analysis module from Image Quant TL software (GE Healthcare, Little
Chalfont, Buckinghamshire, UK); results are expressed in terms of the
ratio of the signal for Imp or Exp relative to that forα/β tubulin in trans-
formed cells, relative to the respective value for the non-transformed
cell line of the isogenic cell pair/set.
2.4. XTT assays
The effect of Impβ1 siRNA on cell proliferation was determined
using the XTT assay as per the manufacturer's instructions. Brieﬂy,
siRNA-treated cell samples were re-seeded onto 96-well assay plates,
retreated with siRNA (as per Section 2.1) and washed at the indicated
time points, and the XTT/PMS reagents (Sigma-Aldrich) incubated in
phenol-free DMEM/F12 Ham's media for 6 h before reading the change
in absorbance at 690 and 450nmusing the FluoSTAROptimaplate read-
er (BMG LabTech). Speciﬁc absorbance was calculated by the following
equation: (OD450 (sample) − OD450 (blank)) − (OD690 (sample) −
OD690 (blank)) and given as the mean (±SD) absorbance calculated
from 5 repeat wells/sample. Themean speciﬁc absorbance was normal-
ised at each time point to that of the non-targeting siRNA-treated con-
trol in each cell line, and the value used as an indicator of cell viability.
2.5. DNA transfection, confocal microscopy and image analysis
The effect of Impβ1 siRNA on nuclear import efﬁciency was deter-
mined using confocal laser scanning microscopy of cells treated with
siRNA as per Section 2.1 followed by transfection to express a βGal-
GFP fusion protein with/without the cytomegalovirus polymerase
pUL54 nuclear localisation sequence (PAKKRAR1159) [25]. Cells were
imaged live (×60 oil immersion objective, zoom of 1.0, 30 μm pinhole,
10% laser power, heated stage) 22–28 h pt using a Nikon TSI 100 confo-
cal laser scanningmicroscope (Nikon, Tokyo, Japan). Image analysis was
performed using the ImageJ v1.41 public domain software (U.S. Nation-
al Institutes of Health, Bethesda, MD, USA) to determine the nuclear
(Fn) cytoplasmic (Fc) and background (Fb) ﬂuorescence. Brieﬂy, a
mean density measurement was made on a region of interest (ROI) of
equal size (ROI = 30 arbitrary units) in the nuclear and cytoplasmic
compartments, respectively, whilst the Fb measurements were made
by placing the ROI on a non-transfected, autoﬂuorescent region near
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cence (Fn/c) was then determined according to the formula: Fn/c =
(Fn− Fb) / (Fc− Fb) [2].
2.6. Flow cytometric analysis and taxol treatment
For analysis of the effect of the siRNAs on cell death and the cell
cycle, MCF10CA1h cells were plated at 2.3 × 105 cells in 6 cm dishes,
treated with 10 nM Impβ1 or non-targeting siRNA (day 0) and 48 h
later (day 2) detached and 6 × 105 cells seeded onto 10 cm dishes.
The following day (day 3) cells were retreated with siRNA and ﬁxed in
80% ethanol 48 and 72 h later (days 5 and 6 respectively) as required.
In the case of the taxol-treated controls, cells were treated with 1 μg/
ml taxol (Sigma-Aldrich) 3 h prior to ﬁxation. Subsequent to ﬁxing
and RNase A treatment, cells were ﬁltered and stained using propidium
iodide (Sigma-Aldrich) to indicate the DNA content, and the cell cycle/
death proﬁles (2 × 104 cells) were analysed using the LSR II ﬂow
cytometer (BD Biosciences). Quantiﬁcation of the percentage of singlet
cells at different stages of the cell cycle was performed using FlowJo
software (TreeStar Inc., Ashland, OR, USA) and the Dean Jett Fox model.
2.7. Statistical signiﬁcance
The signiﬁcance (p b 0.05) of differences in results between trans-
formed and non-transformed cells was determined using the Student's
(or Welch corrected) t-test for unpaired data (2-tailed p value), as
appropriate using GraphPad Prism (GraphPad Software Inc., La Jolla,
CA, USA).
3. Results
3.1. Hyper-dependence of transformed but not non-transformed cell types
to Impβ1
Real-time RT-qPCR andWestern analysis were applied to theMCF10
tumour progressionmodel of invasive ductal carcinoma. The malignant
MCF10CA1h andMCF10CA1a lines both showed signiﬁcantly (p b 0.05)
higher expression of Impβ1 at both the transcript (Fig. 1a) and protein
(Fig. 1b) levels compared to their non-transformed counterpart, with
the degree of overexpression correlating with the tumour progression
state of the cells.
To test the effect of Impβ1 knockdown on cell proliferation and
viability, we transiently treated the cells of the MCF10 series with
10 nM siRNA (pool of 4) speciﬁc to Impβ1 (Supp. Table S1), followed
by detachment at 48 h post treatment (day 2), and retreatment with
siRNAs 24 h later (day 3), prior to assessment of cell proliferation0.0
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Fig. 1.Elevated expression of Impβ1 inmalignant breast cancer cells. (a) Levels for Impβ1mRNA in
mean± SE (n=4), for expression normalised to the geometric mean of GAPDH and 18S internal
* p b 0.05 vs.MCF10A cells. (b)Western (left) and densitometric (right) analysis of Impβ1 levels in
the signal obtained for Impβ1 normalised to that for α/β tubulin control protein in transformed,using the XTT assay (Fig. 2a) for up to 6 days post retreatment (days
3–9); direct cell counts (Supp. Fig. S1) yielded very similar results.
Although treatment with Impβ1 siRNA decreased the viability of both
malignant and non-transformed cells compared to untreated and non-
targeting siRNA-treated controls (Fig. 2a), this effect was signiﬁcantly
(p b 0.05) more pronounced (c. 6-fold) in the transformed compared
to the non-transformed cell types (Fig. 2b). Strikingly, low doses
(0.5 nM) of siRNA failed to affect the viability of non-transformed
cells, but decreased transformed/tumour cell viability by 50% relative
to non-targeting siRNA-treated controls (Fig. 2c). Dose–response exper-
iments as per Fig. 2a revealed that while nM doses of Impβ1 siRNA de-
creased the number of viable cells for both non-transformed and
malignant lines, doses at, or below 1 nM resulted in selective effects
on malignant but not non-transformed cells (Fig. 2d), with c. 33-fold
higher siRNA potency in tumour compared to non-transformed cells
(estimated absolute LD50 of 0.15 and 5 nM, respectively). To conﬁrm
that the effects were attributable to decreased Impβ1 function, we
employed a different approach, using the Impβ1-speciﬁc inhibitor 2,4-
diaminoquinazoline Importazole (Ipz), which inhibits Impβ1's role in
nuclear import [26]. Signiﬁcantly, Ipz effectively decreased the viability
of malignant MCF10CA1h much more than that of non-transformed
MCF10A cells, in a similar manner to siRNA (Supp. Fig. S2), clearly
implying the speciﬁcity of the effects observed for the Impβ1-speciﬁc
siRNA approaches.
Treating cells with increasing concentrations of Impβ1 siRNA
(Fig. 3a) revealed that Impβ1 silencing was c. 20-fold more efﬁcient in
malignant MCF10CA1h cells than non-transformed MCF10A cells at
day 5 (log growth-phase; Fig. 3b, absolute IC50 of 0.066 compared to
1.3 nM, respectively), with greater silencing efﬁciency also seen in
benign and malignant MCF10AT and MCF10CA1a lines respectively
(Fig. 3cd). The increased efﬁciency of Impβ1 silencing in the trans-
formed lines was not attributable to increased siRNA uptake since all
lines took up siRNA to the same extent (Supp. Fig. S3).
To conﬁrm the ﬁndings in the MCF10 cell system, we used an addi-
tional isogenic transformed cell system; the normal primary human
skin ﬁbroblast cell line 1BR3 together with its SV40 large T-antigen-
transformed counterpart 1BR3.N [23]. Cells were treated with 1 and
10 nM Impβ1 siRNAs and viability measured at day 6 using the XTT
assay. Consistentwith the ﬁndings above, 1 nM Impβ1 siRNA decreased
viability of the transformed 1BR3.N, but not primary 1BR3 cells (Supp.
Fig. S4a); Western/densitometric analysis conﬁrmed efﬁcient silencing
of Impβ1 expression in both primary and transformed cells (Supp.
Fig. S4bc).
Overall, the results suggest that low doses of Impβ1 siRNA selective-
ly decrease viability of different transformed and malignant cell types
but not primary/non-transformed counterparts.0CA1h MCF10CA1a
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Fig. 2. Transformed but not non-transformed breast cell types are hyper-dependent on Impβ1. (a) XTT assays for cells of the MCF10 cell series treated twice with 10 nM Impβ1 or non-
targeting (NT) siRNA, or for untreated (UT) controls at the indicated time points after replating. Results for XTT absorbance are for themean± SD from a single representative experiment
in a series of three experiments. (b) Results for cell viabilitymeasured on day 5 from (a) in non-transformed (white bars) andmalignant cells (grey/black bars) and (c) in cells treatedwith
0.5 nM siRNA. Results represent the ratio of the mean ± SD absorbance relative to NT siRNA-treated cells. * p b 0.0001 vs. MCF10A cells. (d) LD50 curves on day 5 for non-transformed
(white spheres) andmalignant (black spheres) cells treated twice with the indicated concentrations of Impβ1 siRNA. Results are from a single typical experiment in a set of two indepen-
dent experiments.
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To test whether the tumour selectivity of Impβ1 siRNA induced
killing activity reﬂected a general hypersensitivity of tumour cells to
silencing/inhibition of components of the cellular nuclear transport
machinery, we treated non-transformed MCF10A and malignant
MCF10CA1h cells twice with siRNAs (pools of 4 different siRNAs)
targeting Imps other than Impβ1 (Supp. Table S1), including Impα1, α3,
β1, CAS (Cse1l) or Exp-1 (Crm-1) at 1 or 10 nM as required to induce ef-
ﬁcient gene silencing, and monitored viability (Fig. 4a). Although silenc-
ing of Exp-1 and to some extent CAS resulted in signiﬁcantly decreased
viability (p b 0.05) compared to non-targeting siRNA-treated controls,
none of the Imp/Exp siRNAs other than that for Impβ1 (p b 0.05) affected
the malignant cells selectively (Fig. 4a). Impβ1 was efﬁciently silenced in
malignant (c. 50%) but not in MCF10A cells (0%) as expected (1 nM
siRNA), whilst all of the other Imp and Exp proteins showed similar si-
lencing efﬁciency across both cell types (Fig. 4bc). Based on these data,
malignant cells appear to be uniquely hypersensitive to knockdown of
Impβ1, and not affected speciﬁcally by siRNA to other Imps/Exps.3.3. Impβ1 siRNA induces death in malignant cells
Given that the transformed and malignant MCF10 cell types exhibit
c. 2-fold shorter doubling times than the non-transformedMCF10A line
(Supp. Fig. S5) and are hypersensitive to Impβ1 knockdown (see
Section 3.1), and that Impβ1 is known to regulate multiple aspects of
mitosis [20,27], we investigated whether the decreased viability in
Impβ1 siRNA-treated cells may be associated with a block in cellcycle/mitotic progression and whether this relates to the induction of
cell death. To this end, we performed propidium iodide staining of ma-
lignant MCF10CA1h cells treated twice with 10 nM Impβ1 siRNA
followed by ﬂow cytometry (Fig. 5a) and DNA content analysis
(Fig. 5b) on day 4 or day 5 corresponding to time points of the XTT
assay in Fig. 2. Impβ1 siRNA signiﬁcantly (p b 0.05) increased the sub-
G1 population compared to untreated and non-targeting siRNA-
treated controls on day 5 but not day 4 (Fig. 5b). No signiﬁcant differ-
ences were observed in the G2/M or S phase populations in cells treated
with Impβ1 or non-targeting (control) siRNA on either day (Fig. 5b). In
contrast, cells that had been treated with the microtubule-stabilising
agent taxol showed an increase and decrease in the G2/M and G1 pop-
ulations respectively, indicative of G2/M phase arrest (Fig. 5b). These
data suggest Impβ1 siRNA's growth inhibitory effects on malignant
cells are due to the induction of cell death, but do not relate to perturba-
tion of cell cycle progression.
3.4. Impβ1 siRNA decreases nuclear import efﬁciency in malignant but not
in non-transformed cells
Impβ1 is known to mediate nuclear protein import in interphase
cells [19]. We visualised the effects of Impβ1 siRNA (10 and 1 nM) on
nuclear accumulation of a large, c. 480 kDa βGal-GFP-fusion protein
(βGal-NLS-GFP) containing the Impα/β1-recognised NLS from the
human cytomegalovirus DNA polymerase catalytic subunit pUL54 [25]
or βGal-GFP alone in non-transformed MCF10A and malignant
MCF10CA1h cells treated twice with Impβ1 or non-targeting control
siRNA on day 6, by live cell confocal laser scanning microscopy (Fig. 6a),
and used image analysis to determine the nuclear-to-cytoplasmic-
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1874 H.V. Kuusisto, D.A. Jans / Biochimica et Biophysica Acta 1853 (2015) 1870–1878ﬂuorescence ratio (Fn/c; Fig. 6b). The level of βGal-NLS-GFP nuclear accu-
mulation was signiﬁcantly (p b 0.0001) c. 5-fold decreased by Impβ1
siRNA-treatment in malignant MCF10CA1h cells compared to non-
targeting siRNA treated controls, bringing the extent of nuclear accumula-
tion to levels identical to those in the non-transformed MCF10A cells
(Fig. 6ab); Impβ1 siRNA did not impact on nuclear accumulation in the
latter. Consistent with the idea that the impact of Impβ1 knockdown on
βGal-NLS-GFP transport was not due to effects at the level of the nuclear
envelope/NPC, the βGal-GFP control protein remained strongly cyto-
plasmic in the presence or absence of Impβ1 siRNA treatment in
both cell lines (Fig. 6ab). The clear implication is that the higher
levels of Impβ1 in the malignant cells are directly responsible for
the higher nuclear accumulation efﬁciency observed, as compared
to non-transformed cells.4. Discussion
We show here for the ﬁrst time that Impβ1 siRNA is highly potent in
inhibiting the proliferation of basal type tumour cells arising fromductal
epithelia and transformed primary cells, but not their non-transformed
isogenic counterparts, although at higher (≥10 nM) doses we observed
partial decreases in viability even in normal/non-transformed cell types.
Intriguingly, this hypersensitivity is evident even though malignant
cells express higher levels of Impβ1 transcript/protein [2–5]. That the
results are not unique to siRNA approaches is indicated by the hyper-
sensitivity of malignant cells to a small molecule inhibitor of Impβ1
(Supp. Fig. S2).
Impβ1 plays a central role in nuclear trafﬁcking of important signal-
lingmolecules such as transcription factors through action alone, or as a
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Fig. 4. Tumour-enhanced silencing and cell killing activity is speciﬁc to Impβ1 siRNA. (a) Viability of non-transformedMCF10A andmalignantMCF10CA1h cells treated twicewith 1 (left)
or 10 (right) nM siRNA for the indicated Imp/Exp or non-targeting (NT) control was measured using the XTT assay on day 5 as per Fig. 2b. * p b 0.05 vs. MCF10A cells. (b) Western and
(c) densitometric analysis of Imp expression in samples from (a) in cells treated with 1 or 10 nM siRNAs as per Fig. 3. Results are from a single representative experiment in a series
of≥ 4 separate experiments. UT, untreated.
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Imp7. It is also a key driver of mitotic exit and G1 phase progression.
We found that treatment of cells with Impβ1 siRNA selectively de-
creased nuclear import efﬁciency and induced cell death in malignant
but not in non-transformed cells, without signiﬁcant effects on the
number of cells undergoing mitosis. The precise mechanism of tumour
cell hypersensitivity to reduced levels of Impβ1 is not clear, but presum-
ably relates to these key cellular roles of Impβ1 distinct from those of
other Imps/Exps, and the fact that faster growing tumour cells, although
expressing higher levels of Impβ1, are more dependent on (“addicted
to”) Impβ1 than non-transformed cells. Comparable tumour cell “addic-
tion” has been observed for other cellular factors, oncogenic or otherwise,
such as cyclin D1 [29], c-myc [30], DNA damage response kinases ATM
[31] and CHK1 [32], and the reactive oxygen species (ROS)-inhibiting py-
ruvate dehydrogenase kinase [33], whereby targeting these factors by
RNAi or small molecular inhibitors results in selective cancer cell death.
As for these factors, increased Impβ1 levels may be critical to support on-
cogenic tumour promoting functions driving cell cycle progression and
proliferation in transformed cells, whilst being less critical in non-
transformed cell types. The results here suggest that the mechanistic
basis is the reliance on elevated Impα/β1-dependent nuclear import efﬁ-
ciency by malignant cells; that Imp levels can contribute critically totumour promotion has been shown for the oncoprotein c-myc and the
transcription factor E2F1 [34,35].
The basis of the increased sensitivity of the tumour cells to Impβ1
knockdown at low siRNA concentrations is not clear, especially as the
breast tumour cell types in this study replicate faster than non-
transformed MCF10A cells, which can result in the dilution of siRNA,
and have a higher abundance of Impβ1 transcript and protein in un-
treated cells, both of which can negatively impact RNAi efﬁciency [36,
37]. Signiﬁcantly, this is clearly not a generalised mechanism, as we
found that silencing of other Imp and Exp proteins was similar in
MCF10CA1h tumour compared to non-transformed cells thus improved
silencing may relate to inherent differences in target recognition/indi-
vidual siRNA potencies etc.
Targeting the components of the nuclear transport system through
inhibition of nuclear transporter activity is already underway in preclin-
ical and clinical trials for SINEs (selective inhibitors of nuclear export),
which are small molecular inhibitors that target the activity of the
Impβ1-homologue Exp-1 (Crm-1) [38], although the realistic utility of
these novel leptomycin B [39] like molecules in a clinical context re-
mains to be established, predominantly of their high toxicity [40]. Our
studies in transformed breast and skin cells indicate that targeting
Impβ1 using siRNA is highly toxic to tumour but not non-transformed
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may prove useful in other cancer cell and animal models, and whether
targeting of Impβ1 may also be used in therapy. That the anti-
proliferative activity of tumour suppressors such as p53, pRb,
BRCA1 and p27kip is strongly dependent on nuclear localisation
through Impα/β1 [14,16,41,42] is a potential concern in this con-
text, but since many of these suppressors are inactivated in highly
malignant cell types due to genetic abnormalities [43], this is pre-
sumably not a major factor. Indeed, the present study indicates the
striking hypersensitivity of malignant cells to approaches targeting
Impβ1, consistent with other published observations for lung carcinoma,
head and neck carcinoma cells [44] and cervical cancer lines [4,45].
Whether targeting Impβ1 transport activity by smallmolecular inhibitors
or siRNAs can induce selective tumour killing in vivo, is an exciting ques-
tion for future consideration.
5. Conclusion
In conclusion, this is the ﬁrst comprehensive demonstration of
hypersensitivity of isogenic tumour compared to normal cell types to
Impβ1 inhibition in a disease progression model of human basal type
breast carcinoma. Future work in this laboratory is aimed at pursuing
the observations here to assess their potential application in tumour
selective therapies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.05.002.
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